AI Summary
Sobi reported Q2 2026 revenue of SEK 7,842M, up 27–29% CER, led by haematology and immunology. Doptelet and Altuvoct boosted haematology; Gamifant and Kineret fueled immunology, while the strategic portfolio advanced 53% CER. The company raised 2026 guidance to mid-to-high-teens revenue growth and mid-to-high 30s EBITA, underscoring momentum ahead of pivotal pipeline milestones, including REDUCE 2 data and NASP manufacturing progress.
Sentiment Rationale
Strong topline growth across segments, margin expansion, and higher guidance typically drive short- to intermediate-term upside; NASP/REDUCE 2 catalysts provide optionality but COVID- or manufacturing-related risks temper move.
Trading Thesis
Bullish; maintain long exposure into 2H26 on accelerating growth and pipeline catalysts.
Market-Moving
- Haematology and immunology momentum supports margin expansion and profitability.
- Pozdeutinurad REDUCE 2 topline results provide upside optionality.
- NASP manufacturing CRL presents near-term execution risk.
- Guidance upgrade to mid-to-high-teens revenue and mid-to-high 30s EBITA supports valuation.
Key Facts
- Q2 revenue SEK 7,842M; CER +29%, actual +27%; haematology- and immunology-led growth.
- Haematology SEK 5,726M; Doptelet and Altuvoct key drivers.
- Immunology SEK 1,711M; Gamifant and Kineret strong contributors.
- Strategic portfolio up 53% CER; adjusted EBITA margin 35%.
- Outlook raised: mid-to-high-teens revenue growth; mid-to-high-30s EBITA; NASP/REDUCE 2 catalysts.
Companies Mentioned
- Swedish Orphan Biovitrum AB (SOBI): Q2 results beat growth expectations; significant pipeline progress and upgraded guidance.
Earnings
Category: Earnings. The release centers on quarterly results, profitability metrics, and updated 2026 outlook, with pipeline progress as a forward catalyst.